Oral polychemotherapy to induce remission in newly diagnosed type 2 diabetes: results from a randomized controlled trial.
Alessandra Dei Cas, Raffaella Aldigeri, Giuseppe Maglietta et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the efficacy of a four-drug regimen (POLYCHEM) compared to standard diabetes care (SDC) in inducing remission in newly diagnosed type 2 diabetes patients. Conducted in six Italian clinics, the study found that after 16 weeks, 90.0% of POLYCHEM patients achieved regression of diabetic hyperglycemia versus 77.1% in the SDC group (p=0.002), but remission rates at 12 weeks post-treatment were not significantly different.
Key findings
- 90.0% of POLYCHEM patients achieved regression of diabetic hyperglycemia compared to 77.1% in SDC (p=0.002).
- At visit 3, 38.3% of POLYCHEM patients achieved diabetes remission versus 43.8% in SDC (p=0.59).
- The upper 95% CI for POLYCHEM remission was 50.9%, while the lower 95% CI for SDC was 30.4%, indicating a potential difference of 20.5%.
Why it matters
Understanding the effectiveness of different treatment regimens for newly diagnosed type 2 diabetes is crucial for optimizing patient outcomes. This study suggests that a more complex four-drug regimen may not provide additional benefits over standard care in achieving long-term remission.